Wells Fargo & Company Eagle Pharmaceuticals, Inc. Transaction History

Wells Fargo & Company

  • $407 Billion
  • Q2 2024

A detailed history of Wells Fargo & Company transactions in Eagle Pharmaceuticals, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 351 shares of EGRX stock, worth $1,554. This represents 0.0% of its overall portfolio holdings.

Number of Shares
351
Previous 4,007 91.24%
Holding current value
$1,554
Previous $20,000 95.0%
% of portfolio
0.0%
Previous 0.0%

Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024
SELL
$3.34 - $5.6 $12,211 - $20,473
-3,656 Reduced 91.24%
351 $1,000
Q1 2024

May 10, 2024
BUY
$4.26 - $6.51 $3,288 - $5,025
772 Added 23.86%
4,007 $20,000
Q4 2023

Feb 09, 2024
BUY
$4.63 - $15.21 $2,731 - $8,973
590 Added 22.31%
3,235 $16,000
Q3 2023

Nov 13, 2023
SELL
$15.21 - $22.88 $21,050 - $31,665
-1,384 Reduced 34.35%
2,645 $41,000
Q2 2023

Aug 15, 2023
BUY
$17.74 - $31.87 $23,044 - $41,399
1,299 Added 47.58%
4,029 $78,000
Q1 2023

May 12, 2023
BUY
$25.06 - $34.09 $56,284 - $76,566
2,246 Added 464.05%
2,730 $77,000
Q4 2022

Feb 13, 2023
SELL
$24.98 - $39.77 $16,436 - $26,168
-658 Reduced 57.62%
484 $14,000
Q3 2022

Nov 14, 2022
BUY
$26.42 - $47.12 $1,136 - $2,026
43 Added 3.91%
1,142 $31,000
Q2 2022

Aug 12, 2022
SELL
$41.26 - $51.35 $1.69 Million - $2.1 Million
-40,960 Reduced 97.39%
1,099 $48,000
Q1 2022

May 16, 2022
SELL
$44.58 - $52.6 $88,981 - $104,989
-1,996 Reduced 4.53%
42,059 $2.08 Million
Q4 2021

Feb 14, 2022
SELL
$45.82 - $56.9 $10.1 Million - $12.5 Million
-219,766 Reduced 83.3%
44,055 $2.24 Million
Q3 2021

Nov 15, 2021
BUY
$43.79 - $55.78 $3.94 Million - $5.02 Million
90,056 Added 51.83%
263,821 $14.7 Million
Q2 2021

Aug 16, 2021
BUY
$36.86 - $44.5 $4.44 Million - $5.36 Million
120,473 Added 226.06%
173,765 $7.44 Million
Q1 2021

May 13, 2021
BUY
$40.32 - $50.97 $322,439 - $407,607
7,997 Added 17.66%
53,292 $2.22 Million
Q4 2020

Feb 09, 2021
BUY
$41.72 - $51.34 $470,017 - $578,396
11,266 Added 33.11%
45,295 $2.11 Million
Q3 2020

Nov 05, 2020
BUY
$37.02 - $51.28 $11,772 - $16,307
318 Added 0.94%
34,029 $1.45 Million
Q2 2020

Aug 13, 2020
BUY
$43.24 - $55.02 $68,621 - $87,316
1,587 Added 4.94%
33,711 $1.62 Million
Q1 2020

May 14, 2020
BUY
$34.37 - $60.07 $1.1 Million - $1.93 Million
32,124 New
32,124 $1.48 Million

Others Institutions Holding EGRX

# of Institutions
79
Shares Held
9.89M
Call Options Held
1.01M
Put Options Held
0
View Full List

About EAGLE PHARMACEUTICALS, INC.

EGRX Quotes by TradingView
  • Ticker EGRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 13,015,900
  • Market Cap $57.7M
  • Description
  • Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and in...
More about EGRX
Track This Portfolio

Track Wells Fargo & Company Portfolio

Follow Wells Fargo & Company and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email